AbbVie Presents New Analyzes Evaluating RINVOQ (upadacitinib) in Atopic Dermatitis Based on Patient Characteristics and Body Regions at EADV

NORTHERN CHICAGO, Illinois. – AbbVie (NYSE: ABBV) announced new analyzes of the RINVOQ (upadacitinib) phase 3 clinical trials program in atopic dermatitis to be presented at the 30th European Academy of Dermatology and Virtual Congress of Venereology (EADV). Analysis showed that a greater proportion of patients treated with RINVOQ (15 mg or 30 mg; once daily) with or without topical corticosteroids achieved a 75% improvement in eczema severity index (EASI 75) at week 16 versus placebo, regardless of age, sex, race, weight, disease severity, and previous exposure to systemic therapy.1 Further analysis showed that more patients treated with RINVOQ 30 mg achieved EASI 75 at week 16 compared to dupilumab when measured in four areas of the body.2

“These data further highlight the potential of RINVOQ to help relieve itching and rashes in moderate to severe atopic dermatitis, providing further support for its effectiveness on various patient characteristics and areas of the body,” said Thomas hudson, MD, senior vice president, research and development, scientific director, AbbVie. “Advancing research and encouraging innovation remains at the heart of our efforts to help transform the care of patients with atopic dermatitis, many of whom still suffer from persistent symptoms of the disease despite available treatment options.”

P0183: Efficacy of Upadacitinib for Moderate to Severe Atopic Dermatitis: Stratified Analysis of Three Phase 3 Trials by Key Baseline Characteristics: Study Highlights

In this study, researchers presented results assessing whether the efficacy of RINVOQ observed in global phase 3 clinical trials (Measure Up 1, Measure Up 2, and AD Up) differed based on age, weight, gender, disease severity, race / ethnicity, and treatment history. .1 The analysis observed that for the 15 mg and 30 mg treatment groups, the percentage of patients meeting the primary endpoint of EASI 75 at week 16 in all subgroups was consistent with that observed in the overall study population.1 More than half of all patients for all subgroups (greater than 51%, nominal p